✦ LIBER ✦

Counting the cost of non-compliance with PCI DSS

✍ Scribed by Robert Kidd

Book ID: 114390836
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 95 KB
Volume: 2008
Category: Article
ISSN: 1361-3723
DOI: 10.1016/s1361-3723(08)70163-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The challenges of PCI DSS compliance

✍ James Rees 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 288 KB

PMH52 COSTS OF NON-COMPLIANCE WITH ANTIP

PMH52 COSTS OF NON-COMPLIANCE WITH ANTIPSYCHOTIC MEDICATIONS AMONG PATIENTS WITH SCHIZOPHRENIA

✍ M Salas; A Zuluaga; D Hughes; M Lebmeier; K Vardeva; M Pisu; J Shinogle 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

The costs of compliance with the 1962 FD

The costs of compliance with the 1962 FDA amendments

✍ David Dranove 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 236 KB

POS5 LITERATURE REVIEW ON THE COSTS OF N

POS5 LITERATURE REVIEW ON THE COSTS OF NON-COMPLIANCE IN OSTEOPOROSIS

✍ W Cowell; K Palmer; D Hughes 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB

The impact of non-compliance on the cost

The impact of non-compliance on the cost-effectiveness of pharmaceuticals: a review of the literature

✍ Dyfrig A. Hughes; Adrian Bagust; Alan Haycox; Tom Walley 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 122 KB 👁 1 views

## Abstract Non‐compliance with drug therapies not only limits their effectiveness, but in some instances, is associated with grave clinical sequelae and substantial economic burden. It is important, therefore, to consider non‐compliance in economic evaluations. A review of pharmacoeconomic evaluat

PMDP4: THE INFLUENCE OF NON-COMPLIANCE O

PMDP4: THE INFLUENCE OF NON-COMPLIANCE ON THE EFFECTIVENESS AND COST-EFFECTIVENESS OF DRUG THERAPIES

✍ D Hughes; A Bagust; A Haycox; T Walley 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 53 KB